{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:11:43Z","timestamp":1793193103280,"version":"4.5.0"},"reference-count":38,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Through the experiences gained by accelerating new vaccines for both Ebola virus infection and COVID-19 in a public health emergency, vaccine development has benefited from a \u2018multiple shots on goal\u2019 approach to new vaccine targets. This approach embraces simultaneous development of candidates with differing technologies, including, when feasible, vesicular stomatitis virus or adenovirus vectors, messenger RNA (mRNA), whole inactivated virus, nanoparticle and recombinant protein technologies, which led to multiple effective COVID-19 vaccines. The challenge of COVID-19 vaccine inequity, as COVID-19 spread globally, created a situation where cutting-edge mRNA technologies were preferentially supplied by multinational pharmaceutical companies to high-income countries while low and middle-income countries (LMICs) were pushed to the back of the queue and relied more heavily on adenoviral vector, inactivated virus and recombinant protein vaccines. To prevent this from occurring in future pandemics, it is essential to expand the scale-up capacity for both traditional and new vaccine technologies at individual or simultaneous hubs in LMICs. In parallel, a process of tech transfer of new technologies to LMIC producers needs to be facilitated and funded, while building LMIC national regulatory capacity, with the aim of several reaching \u2018stringent regulator\u2019 status. Access to doses is an essential start but is not sufficient, as healthcare infrastructure for vaccination and combating dangerous antivaccine programmes both require support. Finally, there is urgency to establish an international framework through a United Nations Pandemic Treaty to promote, support and harmonise a more robust, coordinated and effective global response.<\/jats:p>","DOI":"10.1136\/bmjgh-2023-011883","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:20:11Z","timestamp":1685974811000},"page":"e011883","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-1042","authenticated-orcid":false,"given":"Peter J","family":"Hotez","sequence":"first","affiliation":[{"name":"Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[{"name":"CEPI, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9807-2544","authenticated-orcid":false,"given":"Lois","family":"Privor-Dumm","sequence":"additional","affiliation":[{"name":"International Vaccine Access Center, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-2133","authenticated-orcid":false,"given":"Salim","family":"Abdool-Karim","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA) and Department of Epidemiology, Columbia University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didi","family":"Thompson","sequence":"additional","affiliation":[{"name":"CEPI, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-5101","authenticated-orcid":false,"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H","family":"Kim","sequence":"additional","affiliation":[{"name":"International Vaccine Institute, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2025073015233274000_8.6.e011883.1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1698952"},{"key":"2025073015233274000_8.6.e011883.2","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular Stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2025073015233274000_8.6.e011883.3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term Immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025073015233274000_8.6.e011883.4","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-022-04423-8","article-title":"Even after COVID, the world's vaccine strategy is failing","volume":"612","author":"Berkley","year":"2022","journal-title":"Nature"},{"key":"2025073015233274000_8.6.e011883.5","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1016\/S2214-109X(21)00140-6","article-title":"Operation warp speed: implications for global vaccine security","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025073015233274000_8.6.e011883.6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0140-6736(22)01585-9","article-title":"The Lancet Commission on lessons for the future from the COVID-19 pandemic","volume":"400","author":"Sachs","year":"2022","journal-title":"Lancet"},{"key":"2025073015233274000_8.6.e011883.7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042420-112725"},{"key":"2025073015233274000_8.6.e011883.8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-012621-102252"},{"key":"2025073015233274000_8.6.e011883.9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev-med-042420-113212","article-title":"Whole Inactivated virus and protein-based COVID-19 vaccines","volume":"73","author":"Hotez","year":"2022","journal-title":"Annu Rev Med"},{"key":"2025073015233274000_8.6.e011883.10","doi-asserted-by":"crossref","first-page":"101053","DOI":"10.1016\/j.eclinm.2021.101053","article-title":"Global public health security and justice for vaccines and Therapeutics in the COVID-19 pandemic","volume":"39","author":"Hotez","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025073015233274000_8.6.e011883.11","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.126"},{"key":"2025073015233274000_8.6.e011883.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe0948","article-title":"Prospects for a safe COVID-19 vaccine","volume":"12","author":"Haynes","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025073015233274000_8.6.e011883.13","first-page":"100418","article-title":"Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: A retrospective observational study","volume":"17","author":"Santos","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"2025073015233274000_8.6.e011883.14","doi-asserted-by":"crossref","first-page":"03062","DOI":"10.7189\/jogh.12.03062","article-title":"Estimating the impact of vaccination on reducing COVID-19 burden in the United States: December 2020 to March 2022","volume":"12","author":"Sah","year":"2022","journal-title":"J Glob Health"},{"key":"2025073015233274000_8.6.e011883.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00320-6"},{"key":"2025073015233274000_8.6.e011883.16","unstructured":"Privor-Dumm L , Excler J-L , Gilbert DS . n.d. Vaccine access, equity and justice: COVID-19 vaccines and Vaccinations. BMJ Glob Health:under."},{"key":"2025073015233274000_8.6.e011883.17","unstructured":"Excler J-L , Saville M , Privor-Dumm L . n.d. Factors, Enablers, and challenges for COVID-19 vaccine development. BMJ Glob Health:under."},{"key":"2025073015233274000_8.6.e011883.18","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taac063","article-title":"COVID-19 vaccines: the imperfect instruments of vaccine diplomacy","volume":"29","author":"Hotez","year":"2022","journal-title":"J Travel Med"},{"key":"2025073015233274000_8.6.e011883.19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1590\/S1020-49892006000200007","article-title":"Incorporating appropriate technology into North American schools of public health","volume":"19","author":"Hotez","year":"2006","journal-title":"Rev Panam Salud Publica"},{"key":"2025073015233274000_8.6.e011883.20","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"2025073015233274000_8.6.e011883.21","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1016\/j.vaccine.2022.10.045","article-title":"Safety, tolerability and Immunogenicity of biological E's CORBEVAX\u2122 vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, Phase-2\/3 study","volume":"40","author":"Thuluva","year":"2022","journal-title":"Vaccine"},{"key":"2025073015233274000_8.6.e011883.22","unstructured":"CEPI . 321 vaccine candidates against COVID-19 now in development. CEPI; 2020. Available: https:\/\/cepi.net\/news_cepi\/321-vaccine-candidates-against-covid-19-now-in-development\/"},{"key":"2025073015233274000_8.6.e011883.23","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab064","article-title":"India's role in COVID-19 vaccine diplomacy","volume":"28","author":"Sharun","year":"2021","journal-title":"J Travel Med"},{"key":"2025073015233274000_8.6.e011883.24","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/jama.2021.7439","article-title":"Restoring vaccine diplomacy","volume":"325","author":"Hotez","year":"2021","journal-title":"JAMA"},{"key":"2025073015233274000_8.6.e011883.25","unstructured":"Kansteiner F . Aspen Pharmacare, pursuing J&J vaccine license, aims to shore up local capacity and quash shot inequality in Africa. Fierce Pharma 2021 https:\/\/www.fiercepharma.com\/manufacturing\/j-j-covid-19-partner-aspen-pharmacare-eyes-looks-to-shore-up-local-capacity-and-quash"},{"key":"2025073015233274000_8.6.e011883.26","unstructured":"World Health Organization . WHO ANNOUNCES first technology recipients of mRNA vaccine hub with strong support from African and European partners, 2022. Available: https:\/\/www.who.int\/news\/item\/18-02-2022-who-announces-first-technology-recipients-of-mrna-vaccine-hub-with-strong-support-from-african-and-european-partners"},{"key":"2025073015233274000_8.6.e011883.27","unstructured":"Africa CDC . Strategic frameworks: partnerships for African vaccine manufacturing (PAVM) framework for action, n.d.. Available: https:\/\/africacdc.org\/download\/partnerships-for-african-vaccine-manufacturing-pavm-framework-for-action\/"},{"key":"2025073015233274000_8.6.e011883.28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12992-021-00668-6","article-title":"COVID-19 preparedness: capacity to manufacture vaccines, Therapeutics and diagnostics in sub-Saharan Africa","volume":"17","author":"Bright","year":"2021","journal-title":"Global Health"},{"key":"2025073015233274000_8.6.e011883.29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005032","article-title":"Assessing vaccine introduction and uptake Timelines in Gavi-supported countries: are introduction Timelines accelerating across vaccine delivery platforms?","volume":"6","author":"Luthra","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2025073015233274000_8.6.e011883.30","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1016\/j.vaccine.2022.10.044","article-title":"Sustainable vaccine manufacturing in Low- and middle-income countries","volume":"40","author":"Hayman","year":"2022","journal-title":"Vaccine"},{"key":"2025073015233274000_8.6.e011883.31","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fmed.2020.00457","article-title":"The world health organization global Benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage","volume":"7","author":"Khadem Broojerdi","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025073015233274000_8.6.e011883.32","unstructured":"Guzman J , Yadav P . To increase vaccine manufacturing in LMICs, we also need to strengthen regulatory capacity. Center for Global Development 2021 https:\/\/www.cgdev.org\/blog\/increased-vaccine-manufacturing-lmics-we-also-need-strengthen-regulatory-capacity"},{"key":"2025073015233274000_8.6.e011883.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00770-9"},{"key":"2025073015233274000_8.6.e011883.34","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020214","article-title":"Behavioural determinants of COVID-19-vaccine acceptance in rural areas of six Lower- and middle-income countries","volume":"10","author":"Davis","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2025073015233274000_8.6.e011883.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001068","article-title":"Anti-science kills: from Soviet embrace of Pseudoscience to accelerated attacks on US Biomedicine","volume":"19","author":"Hotez","year":"2021","journal-title":"PLoS Biol"},{"key":"2025073015233274000_8.6.e011883.36","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-022-00104-8"},{"key":"2025073015233274000_8.6.e011883.37","doi-asserted-by":"crossref","first-page":"e1232","DOI":"10.1016\/S2214-109X(22)00278-9","article-title":"Why we still need a pandemic treaty","volume":"10","author":"Hannon","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2025073015233274000_8.6.e011883.38","unstructured":"The Global Partnership for Financial Inclusion (GPFI). G20 Rome leaders. Declaration 2021 https:\/\/www.gpfi.org\/news\/g20-rome-leaders-declaration-0"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2023-011883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:23:41Z","timestamp":1753914221000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2023-011883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,5]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjgh-2023-011883"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2023-011883","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}